Delivery Order SPE2DB20D3101-SPE2DB25FRWR3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) with a ceiling value of $16,944.57. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by September 12, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $3,819.87 delivery order to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $8,139.90 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) on September 8, 2025, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price delivery order is non-set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The order represents a single transaction under AmerisourceBergen Drug Corp's existing contract...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count package) at a ceiling value of $3,756.36. This firm fixed price delivery order represents a non-competitive set-aside and is scheduled for completion by September 12, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, leveraging the company's established...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets in quantities of 90 units. This firm fixed-price delivery order, valued at $1,351.98, represents a competitive award with no set-aside designation and is scheduled for completion by September 10, 2025. The contract is being fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,362.54 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) on August 18, 2025, with completion expected by August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open contracting vehicle. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $36,196.14 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 12, 2025, with completion targeted for August 13, 2025. This firm fixed-price delivery order was awarded without set-aside designation through competitive procedures and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Valsartan-HCTZ 160-25 mg tablets in quantities of 90 units, with a ceiling value of $3,305.82. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 8, 2025. The award was made to AmerisourceBergen Drug Corp at its Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Valsartan-HCZ 320-25 mg tablets (90-count) with a ceiling value of $3,727.23. This is a firm fixed price, non-set-aside delivery order that represents a single transaction under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $5,582.42 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 19, 2025, with completion scheduled for August 20, 2025. This non-competitive delivery order utilizes firm fixed pricing and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRWR3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Valsartan-HCTZ 320-12.5 mg tablets (90-count) with a ceiling value of $6,931.74 under firm fixed-price terms. This is a non-set-aside, competitively awarded contract with an ultimate completion date of September 29, 2025, and performance will be executed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The IDC enables AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen is a major pharmaceutical distributor and critical vendor for federal medical procurement, with a demonstrated capability to fulfill open competition requirements across multiple therapeutic domains through its extensive portfolio of federal contract awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.9k | 9/26/25 |